Every GLP-1 conversation eventually arrives at the same question: tirzepatide or semaglutide?
These are the two molecules that define modern obesity and diabetes pharmacotherapy. They're made by different companies, work through partially different mechanisms, and — thanks to a landmark head-to-head trial — we now have direct comparison data instead of guesswork.
This isn't Ozempic vs Mounjaro (those are brand names with specific approved uses). This is the molecule-level comparison. Because whichever molecule you end up on, you might encounter it under several brand names.
The molecules and their brands
Semaglutide (Novo Nordisk):
- Ozempic — type 2 diabetes, injection
- Wegovy — weight management, injection (2.4mg) and pill (25mg)
- Wegovy HD — weight management, injection (7.2mg), approved March 2026
- Rybelsus — type 2 diabetes, pill (3mg, 7mg, 14mg)
- Generic semaglutide — coming in 2026 following patent expiry
Tirzepatide (Eli Lilly):
- Mounjaro — type 2 diabetes, injection
- Zepbound — weight management, injection
- No pill version yet (though orforglipron, Lilly's oral GLP-1, is under FDA review)
How they work: one hormone vs two
Semaglutide is a GLP-1 receptor agonist. It mimics GLP-1, a gut hormone that tells your brain you're full, slows stomach emptying, and improves insulin secretion.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP enhances insulin secretion, improves fat metabolism, and appears to work synergistically with GLP-1 signalling. The dual-agonist approach is why tirzepatide generally produces greater weight loss and metabolic improvements than semaglutide alone.
Both are administered once weekly via subcutaneous injection. Both use a dose-escalation protocol to minimise gastrointestinal side effects.
Weight loss: the head-to-head data
The SURMOUNT-5 trial settled the debate with direct comparison data. At maximum approved weight-loss doses over 72 weeks, tirzepatide (15mg) produced 20.2% mean body weight reduction versus 13.7% for semaglutide (2.4mg). Roughly 35% of tirzepatide participants lost 25% or more of their body weight, compared to about 10% of semaglutide participants (Aronne et al., 2025).
That's a substantial difference. For a 120kg person, the gap translates to roughly 8kg (17.6lbs) more weight loss with tirzepatide.
However, the comparison landscape has shifted. Wegovy HD (semaglutide 7.2mg) was approved in March 2026 and showed 20.7% mean weight loss in the STEP UP trial — nearly matching tirzepatide's SURMOUNT-5 result, though at three times the standard dose (Wharton et al., 2025). At the highest available doses of each molecule, the weight loss gap essentially closes.
Bottom line on weight loss: At standard maximum doses (tirzepatide 15mg vs semaglutide 2.4mg), tirzepatide produces significantly more weight loss. At the highest available semaglutide dose (7.2mg), the results converge. Dose matters as much as molecule.
Blood sugar control
Both molecules are powerfully effective for type 2 diabetes, but tirzepatide has consistently shown an edge.
In the SURPASS trials, tirzepatide at 15mg reduced HbA1c by up to 2.4 percentage points, with over 90% of participants reaching HbA1c below 7%. Semaglutide typically achieves 1.5-1.8 percentage point reductions at standard doses. This difference is clinically meaningful for many patients with type 2 diabetes.
In the head-to-head ACHIEVE-3 trial, Eli Lilly's oral GLP-1 (orforglipron) also outperformed oral semaglutide on HbA1c reduction (~2.2 vs ~1.4 percentage points), further suggesting Lilly's GLP-1 platform has a consistent glycaemic advantage.
Side effects compared
The gastrointestinal side effect profile is broadly similar: nausea, vomiting, diarrhoea, constipation, and abdominal pain are common with both molecules. These effects are most intense during dose escalation and typically improve at stable doses.
A comprehensive gastrointestinal tolerability analysis across the SURMOUNT trials confirmed that nausea peaked during dose increases and generally resolved within weeks (Rubino et al., 2025). The pattern with semaglutide is comparable.
Some nuances:
Tirzepatide may cause slightly more diarrhoea and slightly less nausea than semaglutide for some patients — though individual variation is enormous. Some people who couldn't tolerate one molecule do perfectly well on the other.
Semaglutide 7.2mg (Wegovy HD) introduced a new side effect: dysaesthesia (altered skin sensation described as sensitivity, pain, or burning). This occurred more frequently at the higher dose and generally resolved on its own or with dose reduction. This hasn't been reported as a significant concern with tirzepatide.
Both molecules carry similar rare risks: pancreatitis, gallbladder problems, and a theoretical thyroid C-cell tumour risk based on animal studies (not confirmed in humans).
Beyond weight loss: additional indications
This is where semaglutide currently leads.
Semaglutide's proven indications:
- Type 2 diabetes
- Chronic weight management
- Cardiovascular risk reduction (SELECT trial: 20% MACE reduction) (Lincoff et al., 2023)
- MASH/NASH (fatty liver disease) — FDA-approved 2025
- Chronic kidney disease — FDA/EMA-approved 2025
Tirzepatide's proven indications:
- Type 2 diabetes
- Chronic weight management
- Obstructive sleep apnoea — FDA-approved 2025
Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is still ongoing. Until those results are published, semaglutide has the advantage in cardiac evidence. Both molecules are being studied in additional conditions — the pipeline of potential new indications is enormous for the entire GLP-1 class.
Cost and access: the patent divide
Here's where the competitive dynamics get interesting in 2026.
Semaglutide's core US patent expired March 20, 2026. Generic manufacturers have filed applications. The first FDA-approved generic semaglutide products could reach pharmacies within months. When generic competition arrives, injectable semaglutide prices will fall dramatically — historically 30-80% below brand pricing initially, dropping further over time.
Tirzepatide remains fully patent-protected through the early 2030s. There will be no generic tirzepatide for years.
This creates a real fork in the road. Do you choose the molecule with better weight loss data at standard doses but a higher, locked-in price? Or the molecule that's about to become dramatically cheaper, with an ultra-high-dose option (7.2mg) that closes the efficacy gap?
Current pricing:
- Semaglutide (Ozempic): ~$900-1,000/month
- Semaglutide (Wegovy injection): ~$1,300/month list (as low as $245 with discounts)
- Semaglutide (Wegovy pill): $149-$299/month cash pay
- Tirzepatide (Mounjaro/Zepbound): ~$1,000-1,100/month
When generics arrive, semaglutide could be available for $250-$600/month initially, dropping further.
The pipeline: what's coming
For semaglutide: CagriSema (semaglutide + cagrilintide, a combination of GLP-1 and amylin) has been submitted for FDA approval. If approved, it would offer even greater weight loss from the semaglutide platform.
For tirzepatide: Retatrutide is Eli Lilly's next-generation triple agonist (GIP/GLP-1/glucagon) that showed up to 28.7% weight loss in phase 3 trials. Regulatory submission is expected in 2026. If approved, it would significantly leapfrog both current molecules.
Oral competition: Eli Lilly's orforglipron (oral, non-peptide GLP-1) is under FDA review with expected approval in 2026. It doesn't require fasting or water-timing restrictions like oral semaglutide. This could reshape the oral GLP-1 market.
Making the choice
Tirzepatide is likely better if: Maximum weight loss at standard doses is your priority. You have type 2 diabetes with difficult-to-control blood sugar. You haven't responded well enough to semaglutide. Cost is not the deciding factor.
Semaglutide is likely better if: You want the broadest range of proven benefits (cardiovascular, kidney, liver). You prefer a pill option. Cost sensitivity matters (generics are coming, and the Wegovy pill is already affordable). You have cardiovascular disease and want the most evidence-backed cardiac protection. Long-term safety data depth matters to you (semaglutide has been studied since 2012).
Neither is "better" in absolute terms. They're both extraordinary medications that have transformed how we treat obesity and diabetes. Your specific health profile, treatment goals, insurance coverage, and body's response will determine which is right for you.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from.
-
Aronne et al. (2025) — The SURMOUNT-5 head-to-head trial directly comparing tirzepatide vs semaglutide at maximum approved weight-loss doses. Tirzepatide produced 20.2% vs 13.7% weight loss over 72 weeks. Read the full study
-
Wharton et al. (2025) — The STEP UP trial showing high-dose semaglutide 7.2mg achieved 20.7% mean weight loss, closing the gap with tirzepatide at the highest available dose. Read the full study
-
Lincoff et al. (2023) — The SELECT trial demonstrating semaglutide reduced major adverse cardiovascular events by 20%, giving semaglutide the strongest cardiac outcome evidence in the class. Read the full study
-
Rubino et al. (2025) — Comprehensive GI tolerability analysis across the SURMOUNT tirzepatide trials, confirming nausea peaks during dose escalation and resolves at stable doses. Read the full study
-
Wilding et al. (2021) — The foundational STEP 1 trial establishing semaglutide 2.4mg as an effective weight-loss treatment with 14.9% mean weight loss over 68 weeks. Read the full study